Advertisement

Research Article Free access | 10.1172/JCI1753

Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39.

R B Gayle 3rd, C R Maliszewski, S D Gimpel, M A Schoenborn, R G Caspary, C Richards, K Brasel, V Price, J H Drosopoulos, N Islam, T N Alyonycheva, M J Broekman, and A J Marcus

Immunex Corporation, Seattle, Washington 98101, USA. gayler@immunex.com

Find articles by Gayle, R. in: JCI | PubMed | Google Scholar

Immunex Corporation, Seattle, Washington 98101, USA. gayler@immunex.com

Find articles by Maliszewski, C. in: JCI | PubMed | Google Scholar

Immunex Corporation, Seattle, Washington 98101, USA. gayler@immunex.com

Find articles by Gimpel, S. in: JCI | PubMed | Google Scholar

Immunex Corporation, Seattle, Washington 98101, USA. gayler@immunex.com

Find articles by Schoenborn, M. in: JCI | PubMed | Google Scholar

Immunex Corporation, Seattle, Washington 98101, USA. gayler@immunex.com

Find articles by Caspary, R. in: JCI | PubMed | Google Scholar

Immunex Corporation, Seattle, Washington 98101, USA. gayler@immunex.com

Find articles by Richards, C. in: JCI | PubMed | Google Scholar

Immunex Corporation, Seattle, Washington 98101, USA. gayler@immunex.com

Find articles by Brasel, K. in: JCI | PubMed | Google Scholar

Immunex Corporation, Seattle, Washington 98101, USA. gayler@immunex.com

Find articles by Price, V. in: JCI | PubMed | Google Scholar

Immunex Corporation, Seattle, Washington 98101, USA. gayler@immunex.com

Find articles by Drosopoulos, J. in: JCI | PubMed | Google Scholar

Immunex Corporation, Seattle, Washington 98101, USA. gayler@immunex.com

Find articles by Islam, N. in: JCI | PubMed | Google Scholar

Immunex Corporation, Seattle, Washington 98101, USA. gayler@immunex.com

Find articles by Alyonycheva, T. in: JCI | PubMed | Google Scholar

Immunex Corporation, Seattle, Washington 98101, USA. gayler@immunex.com

Find articles by Broekman, M. in: JCI | PubMed | Google Scholar

Immunex Corporation, Seattle, Washington 98101, USA. gayler@immunex.com

Find articles by Marcus, A. in: JCI | PubMed | Google Scholar

Published May 1, 1998 - More info

Published in Volume 101, Issue 9 on May 1, 1998
J Clin Invest. 1998;101(9):1851–1859. https://doi.org/10.1172/JCI1753.
© 1998 The American Society for Clinical Investigation
Published May 1, 1998 - Version history
View PDF
Abstract

Excessive platelet accumulation and recruitment, leading to vessel occlusion at sites of vascular injury, present major therapeutic challenges in cardiovascular medicine. Endothelial cell CD39, an ecto-enzyme with ADPase and ATPase activities, rapidly metabolizes ATP and ADP released from activated platelets, thereby abolishing recruitment. Therefore, a soluble form of CD39, retaining nucleotidase activities, would constitute a novel antithrombotic agent. We designed a recombinant, soluble form of human CD39, and isolated it from conditioned media from transiently transfected COS-1 cells and from stably transfected Chinese hamster ovary (CHO) cells. Conditioned medium from CHO cells grown under serum-free conditions was subjected to anti-CD39 immunoaffinity column chromatography, yielding a single approximately 66-kD protein with ATPase and ADPase activities. Purified soluble CD39 blocked ADP-induced platelet aggregation in vitro, and inhibited collagen-induced platelet reactivity. Kinetic analyses indicated that, while soluble CD39 had a Km for ADP of 5.9 microM and for ATP of 2.1 microM, the specificity constant kcat/Km was the same for both substrates. Intravenously administered soluble CD39 remained active in mice for an extended period of time, with an elimination phase half-life of almost 2 d. The data indicate that soluble CD39 is a potential therapeutic agent for inhibition of platelet-mediated thrombotic diatheses.

Version history
  • Version 1 (May 1, 1998): No description
Advertisement
Advertisement